Hutch News

Hutch News

Stories tagged 'Philip D Greenberg'

Good News at Fred Hutch

Celebrating faculty and staff achievements

Sept. 14, 2017

An immunotherapy technology developed by Dr. Brian Till with Dr. Oliver Press at Fred Hutchinson Cancer Research Center has been licensed by Mustang Bio Inc., a subsidiary of the biopharmaceutical company Fortress Biotech Inc. The exclusive, worldwide license, announced Sept. 14 by Mustang Bio, will allow a new type of CAR (chimeric antigen receptor) T-cell therapy to be tested in a clinical trial as a treatment for B-cell non-Hodgkin lymphomas. The novel immunotherapy targets CD20, a protein marker on cancer cells in lymphoma.

View story >


Dr. Carl June weaves together HIV and cancer research to advance cures for both

CAR T-cell pioneer and one-time bone marrow transplant fellow will give keynote at HIV cure conference

Aug. 17, 2017 | By Mary Engel / Fred Hutch News Service

Being in two camps — HIV and cancer research — at one time "made a huge, huge impact on me," says immunotherapy researcher Dr. Carl June.

View story >


How cancer fools healthy neighboring cells

‘Tumor microenvironment’ research underscores why we need cancer immunotherapy — and how to make it work for more patients

July 18, 2017 | By Rachel Tompa / Fred Hutch News Service

Like tiny con men, cancer cells have many tricks to fool healthy cells into helping them. Research into the "tumor microenvironment" is uncovering new avenues for treatment.

View story >


Promising results in trial of engineered T cells in high-risk leukemia

High response rates to experimental immunotherapy in patients with treatment-resistant chronic lymphocytic leukemia

July 17, 2017 | By Susan Keown / Fred Hutch News Service

Most patients with recurrent chronic lymphocytic leukemia who were enrolled in a small, early- phase trial saw their advanced tumors shrink or even disappear after an infusion of genetically engineered immune cells. Dr. Cameron Turtle, one of the study’s leaders, presented the results on Saturday at the 2016 annual meeting of the American Society of Hematology in San Diego.

View story >


Forum at Fred Hutch focuses on the hottest developments in cancer immunotherapy

Immune-based treatments move from the fringes to the spotlight

June 16, 2017 | By Susan Keown / Fred Hutch News Service

What's new in cancer immunotherapy? Five hot topics, from new combination therapies to cost.

View story >


Immunotherapy for ovarian cancer shows promise in mouse model, but hurdles remain

‘Tumor microenvironment’ poses unique challenges for T-cell therapy in solid tumors

April 4, 2017 | By Rachel Tompa / Fred Hutch News Service

A major roadblock to adopting T-cell therapy to solid tumors is what’s known as the tumor microenvironment, the local milieu of non-cancerous cells and molecules in and around the tumor. Fred Hutch researcher Dr. Kristin Anderson and her colleagues in Dr. Phil Greenberg's lab are working to overcome those barriers.

View story >



GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.